OvaScience To Host First Quarter 2017 Financial Results Conference Call

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Tuesday, May 9, 2017 to discuss first quarter 2017 financial results and provide a general corporate update.

The live call can be accessed by dialing + 1-888-424-8151 for U.S. callers and + 1-847-585-4422 for international callers five minutes prior to the start of the call and by providing the passcode 8423996. A live webcast of the conference call will be available online from the Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. ET on Tuesday, May 9, 2017 through 11:59 p.m. ET on Tuesday, May 16, 2017, and may be accessed by visiting OvaScience’s website or by dialing + 1-888-843-7419 for U.S. callers and + 1-630-652-3042 for international callers. The replay access code is 8423996#.

About OvaScience

OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaTureSM, a potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections and OvaPrimeSM, which could increase a woman’s egg reserve. OvaScience’s AUGMENTSM treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in select international regions. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com.


Jennifer Viera

Back to news